Dionis Therapeutics

Name

Dionis Therapeutics

Legal name

Dionis Therapeutics

Website

https://dionistx.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Dionis Therapeutics is a private, pre-revenue biotechnology company developing the AMPVax platform, a proprietary technology for faster, lower-cost personalized cancer vaccines with broader neoantigen capture, serving cancer patients across mRNA, virus, cell, DNA, and protein delivery formats.

Ownership category

akta.pro rank

Product category

Personalized Cancer Vaccines

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAAANAK

Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)

Healthcare & Life Sciences/Biotechnology & Biologics/Precision Medicine Solutions

SECONDARYHLAIAEAG

Therapeutic Vaccines (e.g., Cancer/Chronic Infection)

Healthcare & Life Sciences/Pharmaceuticals/Vaccines

SECONDARYHLAAAEAB

Therapeutic Vaccines (cancer, chronic infection immunotherapy)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

SECONDARYHLAAADAA

mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)

Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

SECONDARYHLAAAEAD

Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)

Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

• Personalized cancer vaccines
• Neoantigen vaccine platform
• MRNA vaccine technology
• Cancer immunotherapy
• Vaccine delivery systems

Headquarters

HQ city

Concord

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations

Marketing channels1 record

Core offering

Dionis Therapeutics develops and commercializes the AMPVax platform, a proprietary biomimetic technology for personalized cancer vaccines that mimics the natural starting point for spontaneous immunity. The platform is designed as a plug 'n play solution compatible with virtually all vaccine delivery formats — including mRNA, virus, cell, DNA, and protein — enabling faster, less expensive personalized cancer vaccine development with broader neoantigen capture than alternative approaches.

Differentiator

Problem solved

Functional benefit

Products and services

• AMPVax Platform A disruptive biomimetic technology platform for personalized cancer vaccines that mimics the natural starting point for spontaneous immunity, enabling faster and less expensive vaccine development with broader neoantigen capture. Designed as a plug 'n play solution compatible with virtually all vaccine delivery formats, including mRNA, virus, cell, DNA, and protein, for pharmaceutical and biotechnology partners in immuno-oncology.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Direct peers

• Moderna: Develops personalized mRNA cancer vaccines (mRNA-4157/V940 with Merck) targeting patient-specific neoantigens, directly overlapping Dionis's mRNA-based personalized vaccine approach.
• CureVac: mRNA technology company developing therapeutic cancer vaccines among other applications, directly comparable on mRNA-based personalized cancer vaccine modality.
• BioNTech: Pioneer in individualized mRNA neoantigen cancer vaccines (e.g., BNT122/RO7198457 with Genentech) and the most directly comparable player to Dionis's personalized cancer vaccine focus, though operating at vastly greater scale.
• Gritstone bio: Develops neoantigen-based cancer vaccines using both viral vector and mRNA delivery, with clinical-stage programs in personalized oncology, making it a close direct peer to AMPVax's multi-format platform strategy.

Emerging players

• VBI Vaccines: Develops virus-like particle and enveloped virus vaccine platforms for infectious disease and oncology, comparable as an emerging player in alternative vaccine delivery formats.
• Transgene: Clinical-stage biotech developing viral vector-based therapeutic cancer vaccines (e.g., TG4050, a personalized neoantigen vaccine), directly comparable on personalized viral-vector cancer vaccine approach.
• Immunomic Therapeutics: Develops DNA-based cancer vaccines using the UNITE platform, comparable to AMPVax's claimed compatibility with DNA vaccine delivery formats.
• EpiVax Oncology (EpiVax): Develops neoantigen selection and vaccine design tools for personalized cancer immunotherapy, overlapping with AMPVax's neoantigen-targeting vaccine design approach but focusing on the computational selection layer.
• Anixa Biosciences: Clinical-stage company developing personalized cancer vaccines (especially breast cancer), a comparable emerging player in the patient-specific neoantigen vaccine space.

Broad incumbents

• Bavarian Nordic: Established vaccine company with viral vector-based cancer immunotherapy platforms, comparable as an incumbent in the virus-delivery vaccine format that AMPVax claims to support.

Market position

Customer concentration

• LinkedInlinkedin.com/company/dionis-therapeutics

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dionis Therapeutics